Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

About this update from Compass Therapeutics, Inc.

[{"type":"image","alt":"Compass Therapeutics","displaySize":"","headline":null,"caption":"Compass Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e0q.NZaC1.yytJcmIgZeZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOQ--/https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b","width":300,"height":78}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":58,"olType":false},{"type":"text","content":"BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).","length":532,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Presentation: ","length":41,"tagName":"p"},{"type":"text","content":"Date and Time: Monday, April 27, 2026 at 8:00am ET","length":50,"tagName":"p"},{"type":"text","content":"Toll Free: 1-877-407-9716","length":25,"tagName":"p"},{"type":"text","content":"International: 1-201-493-6779","length":29,"tagName":"p"},{"type":"text","content":"Conference ID: 13760371","length":23,"tagName":"p"},{"type":"text","content":"Webcast Presentation: https://viavid.webcasts.com/starthere.jsp?ei=1761459&tp_key=efc315f5a6","length":96,"tagName":"p"},{"type":"text","content":"A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the “Events” page under the Investors section of the Company’s website.","length":180,"tagName":"p"},{"type":"text","content":"About Compass TherapeuticsCompass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietar...

More updates from Compass Therapeutics, Inc.